Reasoned opinion on the modification of the existing MRL for tebuconazole in poppy seed

Abstract

In accordance with Article 6 of Regulation (EC) No 396/2005, the Czech Republic, hereafter referred to as the evaluating Member State (EMS), received an application from Bayer s.r.o to modify the existing MRL for the active substance tebuconazole in poppy seed. In order to accommodate for the intended use of tebuconazole, the EMS proposed to raise the existing MRL from the limit of quantification 0.05 mg/kg to the proposed MRL of 0.5 mg/kg. The EMS drafted an evaluation report in accordance with Article 8 of Regulation (EC) No 396/2005, which was submitted to the European Commission and forwarded to EFSA. According to EFSA the data are sufficient to derive a MRL proposal of 0.2 mg/kg for the proposed use on poppy seed. Adequate analytical enforcement methods are available to control the residues of tebuconazole in the commodity under consideration. Based on the risk assessment results, EFSA concludes that the proposed use of tebuconazole on poppy seed will not result in a consumer exposure exceeding the toxicological reference values and therefore is unlikely to pose a consumer health risk.